Premium
EFFECT of CB 154 (2‐BROMO‐ALPHA‐ERGOCRYPTINE) ON PARALYSIS AGITANS COMPARED WITH MADOPAR IN A DOUBLE‐BLIND, CROSS‐OVER TRIAL
Author(s) -
Gerlach Jes
Publication year - 1976
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1976.tb04337.x
Subject(s) - hypokinesia , medicine , anesthesia , paralysis , dose , gastroenterology , surgery
Twenty patients with paralysis agitans took part in a double‐blind, cross‐over investigation of CB 154 (2‐bromo‐alpha‐ergocryptine) and Madopar® (L‐Dopa + benserazid (a peripheral decarboxylase inhibitor), dose ratio 4:1). Each treatment phase lasted for 8 weeks. Modapar was found to be significantly superior to CB 154 in the treatment of the Parkinson state as a whole (Webster total score) and the individual symptoms of hypokinesia, rigidity and tremor. Compared with pretreatment score, CB 154 had a weak, but significant effect on tremor, but not on the Webster total score, hypokinesia and rigidity. the effect of CB 154, however, varied: four patients preferred CB 154 to Madopar on account of its satisfactory therapeutic effect and fewer side‐effects (“on‐off” phenomena, hyperkinesia, psychiatric complications); other patients showed neither therapeutic effect nor side‐effects of CB 154, which in some cases may be related to too low a dose‐level of CB 154 (median 30 mg daily, range 20–60 mg). In the four cases first mentioned which showed a good effect of CB 154, the ratio between the dose of CB 154 and the dose of L‐Dopa (in Madopar) was 3.5–10 mg/100 mg, i.e. in certain cases it must be assumed that the maximum dose of CB 154 lies around 120 mg daily.